Determination of Biological Age: Geriatric Assessment vs Biological Biomarkers

Purpose of Review Biological age is the concept of using biophysiological measures to more accurately determine an individual's age-related risk of adverse outcomes. Grading of the degree of frailty and measuring biomarkers are distinct methods of measuring biological age. This review compares these strategies for estimating biological age for clinical purposes. Recent Findings The degree of frailty predicts susceptibility to adverse outcomes independently of chronological age. The utility of this approach has been demonstrated across a range of clinical contexts. Biomarkers from various levels of the biological aging process are improving in accuracy, with the potential to identify aberrant aging trajectories before the onset of clinically manifest frailty. Grading of frailty is a demonstrably, clinically, and research-relevant proxy estimate of biological age. Emerging biomarkers can supplement this approach by identifying accelerated aging before it is clinically apparent. Some biomarkers may even offer a means by which interventions to reduce the rate of aging can be developed.

Automated summary

Biological age, determined by biophysiological measures, is more accurate at assessing an individual's age-related risk of adverse outcomes. Frailty grading and biomarker measurement are two distinct methods to estimate biological age for clinical purposes. Frailty level predicts susceptibility to adverse outcomes, regardless of chronological age, and emerging biomarkers show potential in identifying accelerated aging before clinical manifestation of frailty.